Leveraging a human-integrated mouse organoid platform to identify ERBB signalling as a target in β-catenin mutation-driven hepatocellular carcinoma
Background Although the repertoire of systemic therapies for advanced hepatocellular carcinoma (HCC) continues to expand, patient outcomes remain highly variable and often suboptimal. Emerging evidence suggests that treatment efficacy is significantly influenced by the underlying disease aetiology and specific genetic mutations. Objective Developing scalable preclinical models that accurately reflect human HCC subtypes to advance precision medicine in HCC. Design We employed HCC tumours induced via hydrodynamic tail vein injection of various proto-oncogene and tumour suppressor gene combinations in mice, complemented by a tumour organoid platform, to explore drug repurposing strategies by leveraging driver mutations as biomarkers and to characterise the features of HCC driven by distinct genetic alterations. Results High-throughput screening identified ERBB family inhibitors as promising therapeutic candidates for CTNNB1 mutation-driven HCC. Multi-omics analyses, including chromatin accessibility, transcriptomics and phosphoproteomics, revealed that CTNNB1 mutations upregulate FOXA2 expression, which functions as a transcriptional activator of ERBB signalling-related genes such as EGFR and TGFA, thereby activating the ERBB pathway. Clinically, patients with HCC harbouring CTNNB1 mutations displayed increased FOXA2 expression and ERBB pathway activation. As a proof of concept, treatment with ERBB inhibitors effectively suppressed tumour growth in vivo in mouse models and ex vivo in patient-derived organoids, specifically in HCC driven by CTNNB1 mutations but not in tumours with TP53 mutations. Conclusion Our findings uncover a novel mechanism by which β-catenin activates ERBB signalling in HCC and provide a foundation for repurposing existing drugs, such as gefitinib or afatinib, as targeted therapies for patients with CTNNB1-mutant HCC.
Authors
- Mingdan Deng (ORCID: https://orcid.org/0000-0003-1502-9474)
- Tin Lok Wong (ORCID: https://orcid.org/0000-0003-1147-7958)
- 吴焕文
- Stephen Li (ORCID: https://orcid.org/0000-0003-4287-8172)
- Huajian Yu (ORCID: https://orcid.org/0000-0002-2337-2443)
- Stephanie Ma (ORCID: https://orcid.org/0000-0002-2029-7943)
- Yalin Tu (ORCID: https://orcid.org/0000-0002-6705-683X)
- Jason W.H. Wong (ORCID: https://orcid.org/0000-0003-2953-7728)
- Ernesto Guccione (ORCID: https://orcid.org/0000-0001-7764-5307)
- Lei Zhou (ORCID: https://orcid.org/0000-0003-4709-3198)
- Yan Shu Kong
- Yiling Zhang (ORCID: https://orcid.org/0000-0002-2169-2988)
- Alfred Sze‐Lok Cheng (ORCID: https://orcid.org/0000-0001-5503-5882)
- Frank Fonseca
- Ianto Bosheng Huang (ORCID: https://orcid.org/0009-0007-9919-8414)
- Hiu Yat Yu
- Jiayan Tan
Institutions
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Tisch Cancer Institute (US)
- University of Hong Kong (HK)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Gut
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1136/gutjnl-2025-337370
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00